Lexeo Therapeutics, Inc. (LXEO)
(Delayed Data from NSDQ)
$15.46 USD
-0.02 (-0.13%)
Updated May 24, 2024 04:00 PM ET
After-Market: $15.45 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Lexeo Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 1 | NA | NA | NA |
Cost Of Goods | 0 | 0 | NA | NA | NA |
Gross Profit | 0 | 1 | NA | NA | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 69 | 61 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -69 | -61 | 0 | 0 | 0 |
Non-Operating Income | 2 | 1 | NA | NA | NA |
Interest Expense | 0 | 0 | NA | NA | NA |
Pretax Income | -66 | -59 | NA | NA | NA |
Income Taxes | 0 | 0 | NA | NA | NA |
Minority Interest | 0 | 0 | NA | NA | NA |
Investment Gains/Losses | 0 | 0 | NA | NA | NA |
Other Income/Charges | 0 | 0 | NA | NA | NA |
Income From Cont. Operations | -66 | -59 | NA | NA | NA |
Extras & Discontinued Operations | 0 | 0 | NA | NA | NA |
Net Income (GAAP) | -66 | -59 | NA | NA | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -68 | -60 | 0 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | NA | NA | NA |
Income After Depreciation & Amortization | -69 | -61 | 0 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 5.35 | 1.63 | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -12.40 | -36.36 | NA | NA | NA |
Diluted Net EPS (GAAP) | -12.40 | -36.36 | NA | NA | NA |
Fiscal Year end for Lexeo Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | NA | 0.00 | NA | 0.00 |
Gross Profit | 0.00 | NA | 0.00 | NA | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 23.29 | 0.00 | 20.28 | 0.00 | 19.29 |
Income After SG&A, R&D, and Dept/Amort Expenses | -23.29 | 0.00 | -20.28 | 0.00 | -19.29 |
Non-Operating Income | 1.65 | NA | 0.22 | NA | 0.68 |
Interest Expense | 0.04 | NA | 0.05 | NA | 0.05 |
Pretax Income | -21.68 | NA | -20.11 | NA | -18.66 |
Income Taxes | 0.00 | NA | 0.00 | NA | 0.00 |
Minority Interest | 0.00 | NA | 0.00 | NA | 0.00 |
Investment Gains/Losses | 0.00 | NA | 0.00 | NA | 0.00 |
Other Income/Charges | 0.00 | NA | 0.00 | NA | 0.00 |
Income From Cont. Operations | -21.68 | -14.19 | -20.11 | -13.44 | -18.66 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -21.68 | -14.19 | -20.11 | -13.44 | -18.66 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 27.98 | 16.44 | 1.63 | 1.62 | NA |
Diluted EPS Before Non-Recurring Items | -0.77 | -0.86 | -12.36 | -8.30 | NA |
Diluted Net EPS (GAAP) | -0.77 | -0.86 | -12.36 | -8.30 | NA |